Valeant Pharmaceuticals Intl Inc (VRX) Stock Rating Reaffirmed by Stifel Nicolaus

Author

03 June, 2017

Insiders own 16.37% of the company's stock. The Firm operates through Payment Solutions segment. It has a 16.93 P/E ratio. The Firm allows user to make payments by creating a range of payment solutions and services using its brands, which include MasterCard, Maestro and Cirrus.

Diamond Hill Capital Management Inc decreased Valeant Pharmaceuticals Intern (VRX) stake by 90.04% reported in 2016Q4 SEC filing. In this case, shares are 51.37% higher from $8.31, the worst price in 52 weeks suffered on April 24, 2017, but are collecting gains at -26.69% for the past six months. The institutional investor held 9.49M shares of the health care company at the end of 2016Q4, valued at $137.82 million, down from 11.49 million at the end of the previous reported quarter. Value of 32.00000. Checking in on some valuation rankings, Valeant Pharmaceuticals International, Inc. Hap Trading Limited Co holds 0.94% or 1.29M shares. About 12.27M shares traded. It has underperformed by 65.21% the S&P500.

Some buy side analysts are also providing their Analysis on Valeant Pharmaceuticals International, Inc., where 2 analysts have rated the stock as Strong buy, 0 analysts have given a Buy signal, 13 said it's a HOLD, 5 reported it as Underperform and 0 analysts rated the stock as Sell. Therefore 21% are positive. Royal Bank of Canada restated a "sector perform" rating and issued a $18.00 price target (down previously from $21.00) on shares of Valeant Pharmaceuticals Intl in a research note on Thursday, March 23rd. Guggenheim reiterated a "buy" rating on shares of Valeant Pharmaceuticals Intl in a report on Tuesday, February 7th.

In related news, Director Schutter Richard U. De bought 20,000 shares of Valeant Pharmaceuticals Intl stock in a transaction on Thursday, May 11th.

Stock market analysts watching Valeant Pharmaceuticals International, Inc. Piper Jaffray Companies reiterated an "outperform" rating and issued a $10.00 price objective on shares of Valeant Pharmaceuticals Intl in a report on Friday, April 14th. RBC Capital Markets maintained Valeant Pharmaceuticals Intl Inc (NYSE:VRX) rating on Tuesday, February 14. The firm has "Hold" rating by Scotia Capital given on Thursday, March 23. On Tuesday, November 15 the stock rating was downgraded by FBR Capital to "Mkt Perform". The company was maintained on Wednesday, November 11 by JP Morgan. Pershing Square Cap LP has 18.11 million shares. Broadcom Ltd was raised too.

Investors sentiment decreased to 0.78 in Q4 2016. Its down 0.10, from 0.88 in 2016Q3. It is negative, as 82 investors sold VRX shares while 87 reduced holdings. 49 funds opened positions while 82 raised stakes. The hedge funds in our partner's database now have: 193.03 million shares, down from 222.43 million shares in 2016Q3. Valeant Pharmaceuticals Intern now has $3.91 billion valuation. The net percent change held by Institutional Investors has seen a change of 20.75% in last three month period.

Shares of Frank's global N.V. (NYSE:FI) observed rebound of 11.11% since bottoming out at $7.02 on May. Tci Wealth Advisors has invested 0% in Valeant Pharmaceuticals Intl Inc (NYSE:VRX). Private Group Incorporated has invested 0.56% in Valeant Pharmaceuticals Intl Inc (NYSE:VRX). Gruss & Co. Inc. bought a new position in Valeant Pharmaceuticals Intl during the first quarter worth $104,000. The specialty pharmaceutical company reported $2.80 EPS for the quarter, topping the Zacks' consensus estimate of $0.87 by $1.93.

Now the shares of Valeant Pharmaceuticals International, Inc.

Analysts' mean recommendation for Valeant Pharmaceuticals International, Inc. Hexavest stated it has 0.07% in Valeant Pharmaceuticals Intl Inc (NYSE:VRX). Aspiriant Lc owns 18,868 shares. Moreover, Brandywine Global Invest Mngmt Limited Liability has 0% invested in Valeant Pharmaceuticals Intl Inc (NYSE:VRX) for 1 shares. Stonehill Capital Management Llc, a New York-based fund reported 768,000 shares.#img1#. A low ROE warns that the company is not generating a good return on its reinvested earnings.

Since January 1, 0001, it had 4 insider purchases, and 2 insider sales for $217.81 million activity. Float is the number of shares available for trading of a particular stock. About 11.37 million shares traded. 5,000 shares were bought by Ross Thomas W. Sr.

About 418 shares traded. It has outperformed by 8.14% the S&P500. Mitchell Group Inc owns 486,495 shares or 4.13% of their United States portfolio. The Virginia-based Akre Capital Management Llc has invested 8.91% in the stock. It also increased its holding in Ishares Russell 2000 Etf (IWM) by 2.65M shares in the quarter, for a total of 3.07M shares, and has risen its stake in Vaneck Vectors Gold Miners E. A rating of less than 2 means buy, "hold" within the 3 range, "sell" within the 4 range, and "strong sell" within the 5 range. The lowest target is $99.0 while the high is $126.0. MA was included in 8 notes of analysts from September 8, 2016. The rating was downgraded by TheStreet on Thursday, August 27 to "Buy". The firm has "Neutral" rating by Compass Point given on Monday, October 31. The firm has "Buy" rating by UBS given on Friday, October 30. As per Monday, November 14, the company rating was maintained by Deutsche Bank.


More news